Talquetamab plus daratumumab yields improved patient outcomes in patients with relapsed/refractory multiple myeloma.
Harrison Widelitz
Advertisement
Articles by Harrison Widelitz
Daratumumab-based induction/consolidation and maintenance therapy resulted in durable MRD negativity in patients with newly diagnosed multiple myeloma.
Advertisement
Latest Updated Articles
Talquetamab-Based Triplet Elicits Deep Responses in R/R MyelomaPublished: September 27th 2024 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approval Tees Up T-DXd Plus Pertuzumab as a New SOC in HER2+ Breast Cancer
2
Iberdomide Plus Daratumumab/Dexamethasone Displays High Response Rates in NDMM
3
FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC
4
NALIRIFOX and FOLFIRINOX Facilitate Personalized Treatment in Metastatic Pancreatic Cancer
5